Advanced search
Publication Cover
British Journal of Biomedical Science Volume 73, 2016 - Issue 2
Journal homepage
478
Views
6
CrossRef citations to date
0
Altmetric
Biomedical Science In Brief

Thyroid and parathyroid hormones in benign prostatic hyperplasia

Aneena EldhoseDepartment of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
,
Hanumanthappa NandeeshaDepartment of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IndiaCorrespondence[email protected]
,
Lalgudi. N. DorairajanDepartment of Urology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
,
Karli SreenivasuluDepartment of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
&
S. Arul Vijaya VaniDepartment of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Pages 94-96 | Received 14 Feb 2016, Accepted 26 Mar 2016, Published online: 28 Apr 2016

References

  • Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999;53:1–6.10.1016/S0090-4295(98)00532-9
  • Partin AW. Oesterling: influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J. Urol. 1991;145:405–409.
  • Sanda MG, Beaty TH, Stutzman RE, et al. Genetic susceptibility of benign prostatic hyperplasia. J. Urol. 1994;152:115–119.
  • Hercbergs A. The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia–a novel paradigm. In Vivo. 1996;10:245–247.
  • Hsieh ML, Juang HH. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J. Androl. 2005;26:422–428.10.2164/jandrol.04162
  • Pinto M, Soares P, Ribatti D. Thyroid hormone as a regulator of tumor induced angiogenesis. Cancer Lett. 2011;301:119–126.10.1016/j.canlet.2010.11.011
  • Lehrer S, Diamond EJ, Bajwa AM, et al. Association between serum triiodothyronine (t3) level and risk of disease recurrence in men with localized prostate cancer. Prostate Cancer Prostatic Dis. 2001;4:232–234.10.1038/sj.pcan.4500542
  • Mondul AM, Weinstein SJ, Bosworth T, et al. Circulating thyroxine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoS One. 2012;7:e47730.
  • Lehrer S, Diamond EJ, Stone NN, et al. Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. J. Urol. 2002;168:2431–2433.10.1016/S0022-5347(05)64161-4
  • Skinner HG, Schwartz GG. The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study. Cancer Epidemiol. Biomarkers Prev. 2009;18:2869–2873.10.1158/1055-9965.EPI-09-0730
  • Schwartz GG. Prostate cancer, serum parathyroid hormone and the progression of skeletal metastases. Cancer Epidemiol. Biomark Prev. 2008;17:478–483. 25
  • Ritchie CK, Thomas KG, Andres LR, et al. Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chmotaxis. Prostate. 1997;30:183–187.10.1002/(ISSN)1097-0045
  • Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin. Chim. Acta. 2006;370:89–93.10.1016/j.cca.2006.01.019
  • Mondul AM, Weinstein SJ, Bosworth T. Circulating thyroxine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoS One. 2012;7:1–7.
  • Moeller LC, Broecker-Preuss M. Transcriptional regulation by nonclassical action of thyroid hormone. Thyroid Res. 2011;4:S6.10.1186/1756-6614-4-S1-S6
  • Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr. Rev. 2010;31:139–170.10.1210/er.2009-0007
  • Moeller LC, Dumitrescu AM, Refetoff S. Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1α and glycolytic genes. Mol. Endocrinol. 2005;19:2955–2963.10.1210/me.2004-0542
  • Kim WT, Choi YD, Park C. Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia. Prostate. 2011;71:1210–1215.10.1002/pros.v71.11

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.